

**Literaturverzeichnis zum Titelthema „Neues aus der Pneumologie“  
Bayerisches Ärzteblatt 10/2010, Seite 506 ff  
Dr. Sonja Beckh, Dr. Manfred Wagner und Professor Dr. Joachim H. Ficker**

1. National Emphysema Treatment Trial Research Group. A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348: 2059-2073
2. Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. *J Appl Physiol*. 2009;106:774-783
3. Fessler, H. Collateral damage assessment for endobronchial lung volume reduction. *J Appl Physiol* 106: 755-756, 2009
4. Mantri, S., et al., Measurement of Collateral Flow in the Lung with a Dedicated Endobronchial Catheter System. *J Bronchol Intervent Pulmonol*, 2009. 16(2): p.141-144
5. Hopkinson NS, Toma TP, Hansell DM et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. *Am J Respir Crit Care Med* 2005; 171: 453-460
6. Wood DE, McKenna RJ Jr, Yusef RD et al. A multicenter trial of an intrabronchial valve for treatment of severe emphysema. *J Thorac Cardiovasc Surg* 2007; 133: 65-73
7. Herth FJF, Schmidt B, Ficker JH et al. Germany pilot safety and feasibility study of bronchoscopic thermal vapor ablation (BTVA) for lung volume reduction in patients with heterogeneous emphysema with upper lobe predominance. *Eur Respir J* 2009; 35: A 1827
8. Eberhardt R, Schmidt B, Wagner M, Gompelmann D, Ficker JH, Herth FJF. Deutsche Pilotstudie zur Lungenvolumenreduktion mittels Thermoablation (BTVA) bei Patienten mit heterogenem, oberlappenbetontem Lungenemphysem. *Pneumologie* 2010, 64: S 245
9. Cooper CB, Celli B. Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches, *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2008,5:6,376 - 381
10. Faul JL, Sievert H, Percutaneous Creation of Arteriovenous Shunts. *Vascular Disease Management*, 2008; 5: 128-133
11. Jerrentrup A, Wagner M, Ficker JH, Steier J, Teschler H, Blass H, Pfeifer M, Vogelmeier C für die ROX-Study Group. Erste Erfahrungen mit einer therapeutischen peripheren AV-Fistel bei Patienten mit hochgradiger COPD. *Pneumologie* 2010; 64: S252
12. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2008; 359: 1543 - 1554
13. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009; 180: 948 – 955
14. Beier J, Chanez P, Martinot J-B, Schreurs AJM, Tkáčová, Bao W, Jack D, Higgins M. Safety, tolerability and efficacy of indacaterol, a novel once-daily  $\beta_2$ -agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. *Pulmonary Pharmacology & Therapeutics* 2007; 20: 740 – 749

15. Buhl R, Pieters W, Jack D, Owen R, Kramer B, Higgins M. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. *Am J Respir Crit Care Med* 2009; 179: A6185
16. Beeh KM, Beier J. The short, the long and the "ultra.long": Why duration of bronchodilator action matters in chronic obstructive pulmonary disease. *Adv Ther* 2010 Apr 19
17. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150µg once-daily in COPD: a double-blind, randomized, 12-week study. *BMC Pulm Med* 2010;10:11
18. LaForce C, Korenblat P, Osborne P et al. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma : comparison with placebo and formoterol. *Curr Med Res Opin* 2009; 25: 2353-2359
19. Calverley PMA, Rabe KF, Goehring U-M et al. for the M2-124 M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet* 2009; 374: 685-694
20. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL et al. For the M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. *Lancet* 2009; 374: 695-703
21. Nationale Versorgungsleitlinie Asthma 2009, Kurzfassung, 2. Auflage, März 2010, <http://www.versorgungsleitlinien.de>
22. Ukena D, Fishman L, Niebling WB. Asthma bronchiale – Diagnostik und Therapie im Erwachsenenalter. *Dtsch Arztebl* 2008; 105: A 385 – 94
23. Höffken G, Lorenz J, Kern W, Welte T, Bauer T,, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H. S 3 Leitlinie zu Epidemiologie, Diagnostik, antimikrobieller Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009. Teil 1: *Pneumologie* 2009; 63: 549 – 577; Teil 2: *Pneumologie* 2009; 63: 613 – 652
24. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3 –Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. *Pneumologie* 2010; 64: S 23 – S 155
25. Kohlhäufel M. TNM-Klassifikation 2010. Was ist neu? *Pneumo-News* 2010 (2):10-11
26. Wagner M, Ficker JH (Hrsg.). *Autofluoreszenz-Bronchoskopie: Grundlagen und klinische Anwendung*. Bremen: Uni-Med, 2007
27. Lee P, Brox HAP, Postmus PE, Sudetja TG, Dual digital video-autofluorescence imaging for detection of pre-neoplastic lesions *Lung Cancer* 2007; 58; 44-49
28. Sheski FD, Mathur PN. Endobronchial ultrasound. *Chest* 2008; 133: 264 – 270
29. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. *Chest* 2008; 133:887-891
30. Gomez M, Silvestri GA. Endobronchial ultrasound for the diagnosis and staging of lung cancer. *Proc Am Thorac Soc* 2009; 6: 180 – 186

31. Scagliotti GV, Parikh P, Pawel J von et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2008; 26: 3543–3551
32. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006; 355: 2542–2550
33. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 2009; 361: 958-967
34. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. *Proc Am Soc Clin Oncol* 2009; 27: Abstract 8001
35. Brückl WM, Wiest GH, und Ficker JH. Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC... *Pneumologie* 2010 in press
36. ESC/ERS - Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2009; doi:10.1093/eurheartj/ehp 297
37. Barst RJ, Gibbs JSR, Ghofrani HA, Hoepfer MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *J Am Coll Cardiol* 2009; 54: S78 – 84
38. Galiè N, Rubin LJ, Hoepfer M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet* 2008;371: 2093-2100
39. Mc Laughlin VM, Archer SA, Badesch DB, et al. ACCF/AHA clinical expert consensus document on pulmonary hypertension : a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *J Am Coll Cardiol* 2009; 53: 1573-1619